Related Experiment Video

Updated: Aug 26, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

[Persistent hyperinsulinemic hypoglycemia in infancy: differentiated approach to a heterogeneous syndrome]

P G Voorhoeve1, J L van Wijk, H A Delemarre-van de Waal

  • 1VU Medisch Centrum, afd. Kindergeneeskunde, Postbus 7057, 1007 MB Amsterdam. kinderendo@vumc.nl

Nederlands Tijdschrift Voor Geneeskunde
|February 18, 2004
PubMed

Insights

Persistent hyperinsulinemic hypoglycemia in infancy (PHHI) requires prompt diagnosis and treatment to prevent neurological damage. Differentiating between focal and diffuse insulin hypersecretion guides targeted surgical intervention, avoiding routine pancreatectomy.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Neonatal Care

Background:

  • Persistent hyperinsulinemic hypoglycemia in infancy (PHHI) is a challenging condition characterized by high insulin levels and low ketone bodies during hypoglycemia.
  • Current treatment strategies for PHHI face difficulties, with potential for long-term complications and severe neurological damage.
  • Understanding PHHI pathophysiology is crucial for developing effective management plans.

Discussion:

  • Aggressive pharmacological treatment for 4-6 weeks is recommended before considering surgery, especially given the possibility of transient hyperinsulinism.
  • Routine subtotal pancreatectomy is no longer considered justifiable due to advancements in diagnosis and treatment.
  • Interventional radiology, particularly pancreatic venous sampling, is vital for differentiating focal from diffuse insulin hypersecretion.

Key Insights:

  • Accurate differentiation between focal and diffuse insulin hypersecretion is essential for successful PHHI management.
  • Targeted partial pancreatectomy, guided by imaging, offers a more precise surgical approach than subtotal pancreatectomy.
  • Early and appropriate treatment is critical to prevent irreversible neurological deficits in infants with PHHI.

Outlook:

  • Further research into the long-term outcomes of targeted surgical interventions for PHHI is warranted.
  • Developing novel pharmacological agents could improve the management of transient hyperinsulinism.
  • Enhanced diagnostic imaging techniques may further refine the localization of insulin hypersecretion.

More Related Videos

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test06:59

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Introduction01:26

Diabetes Mellitus: Introduction

Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...